SCHEMBL6471708

SCHEMBL6471708

CC(=O)NC(C)(C)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.46
TSHR P16473 2/20 0.40
ALDH1A1 P00352 1/20 0.40
ELANE P08246 1/20 0.38
EPHX1 P07099 1/20 0.37
KDM4E B2RXH2 3/20 0.35
CA2 P00918 1/20 0.35
PTGS1 P23219 1/20 0.35
MMP12 P39900 1/20 0.35
MAPT P10636 2/20 0.34
NFKB1 P19838 1/20 0.33
NAALAD2 Q9Y3Q0 1/20 0.33
FFAR3 O14843 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
AR P10275 1/20 0.33
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
PKM P14618 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9913287 0.81 EPHX1 (0.40) KDM4CTSHRALDH1A1ELANEEPHX1
SCHEMBL18125958 0.79 KDM4C (0.48) KDM4CTSHRALDH1A1KDM4EMAPT
SCHEMBL11683093 0.78 EPHX1 (0.44) KDM4CTSHRALDH1A1ELANEEPHX1
Acetic Acid SCHEMBL25309382 0.78 ELANE (0.33) KDM4CALDH1A1ELANEEPHX1MAPT
SCHEMBL10493720 0.77 TSHR (0.40) KDM4CTSHRALDH1A1ELANEEPHX1
SCHEMBL14040406 0.74 KDM4C (0.45) KDM4CTSHRALDH1A1KDM4EMAPT
SCHEMBL8471567 0.74 CRBN (0.39) ALDH1A1ELANEEPHX1KDM4ECA2
SCHEMBL29420093 0.74 KDM4C (0.45) KDM4CTSHRALDH1A1KDM4EMAPT
SCHEMBL1132708 0.74 KDM4C (0.45) KDM4CTSHRALDH1A1KDM4ECA2
SCHEMBL11683952 0.74 EPHX1 (0.36) ELANEEPHX1KDM4ECA2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 US claimed
US-20250304643-A1 PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R BAINAN BIOTECH APS (DK) 2025-10-02 US claimed
EP-4583917-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2025-07-16 EP claimed
CN-119923279-A Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof 3B制药有限公司 2025-05-02 CN claimed
CN-119823226-A Application of trichoderma hook antibacterial peptide in prevention and treatment of potato late blight and pesticide 甘肃农业大学 2025-04-15 CN claimed
CN-118027154-B Trichoderma hook T21 antibacterial peptide BI and preparation method and application thereof 甘肃农业大学 2024-11-22 CN claimed
CN-118843639-A Peptide dual agonists of GIPR and GLP2R 白南生物技术有限公司 2024-10-25 CN claimed
EP-4448097-A1 PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R Bainan Biotech ApS (DK) 2024-10-23 EP claimed
CN-117986326-B Trichoderma hook T21 antibacterial peptide BII and preparation method and application thereof 甘肃农业大学 2024-09-17 CN claimed
CN-117986326-A Trichoderma hook T21 antibacterial peptide BII and preparation method and application thereof 甘肃农业大学 2024-05-07 CN claimed
WO-2024052431-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2024-03-14 WO claimed
WO-2023111273-A1 PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R BAINAN BIOTECH APS (DK) 2023-06-22 WO claimed
CN-114981295-A Polypeptide compound and application thereof 联邦生物科技(珠海横琴)有限公司 2022-08-30 CN claimed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 WO claimed
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 US disclosed
EP-4143179-B1 AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER IDORSIA PHARMACEUTICALS LTD (CH) 2025-10-22 EP disclosed
US-20250304643-A1 PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R BAINAN BIOTECH APS (DK) 2025-10-02 US disclosed
EP-0015772-A1 N-(2-((acylaminoacylamino or aminoacylamino)phenyl)-4-hydroxy-5-pyrimidinylcarbonyl)cephalosporin compounds, processes for their production, and compositions containing the same WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed
EP-0015771-A1 N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed
EP-0015773-A2 N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF KLK3, FOLH1, PSMA1 KDM4C 3667/4885TSHR 540/4885ALDH1A1 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.